Takeda Pharmaceutical (NYSE:TAK) Sets New 12-Month Low at $13.08

Takeda Pharmaceutical Company Limited (NYSE:TAK) shares reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $13.08 and last traded at $13.11, with a volume of 294162 shares. The stock had previously closed at $13.23.

Takeda Pharmaceutical Stock Down 0.3 %

The company has a current ratio of 1.06, a quick ratio of 0.55 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $41.25 billion, a PE ratio of 19.75, a P/E/G ratio of 2.98 and a beta of 0.53. The stock’s fifty day simple moving average is $14.06 and its 200-day simple moving average is $14.20.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Thursday, February 1st. The company reported $0.51 earnings per share (EPS) for the quarter. The firm had revenue of $7.52 billion for the quarter. Takeda Pharmaceutical had a net margin of 6.90% and a return on equity of 12.57%. As a group, sell-side analysts forecast that Takeda Pharmaceutical Company Limited will post 1.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Takeda Pharmaceutical

A number of hedge funds have recently made changes to their positions in the business. Sage Rhino Capital LLC bought a new stake in shares of Takeda Pharmaceutical during the 1st quarter worth $164,000. Aaron Wealth Advisors LLC bought a new stake in shares of Takeda Pharmaceutical during the 1st quarter worth $293,000. Simplicity Wealth LLC bought a new stake in shares of Takeda Pharmaceutical during the 1st quarter worth $4,008,000. BSW Wealth Partners raised its stake in shares of Takeda Pharmaceutical by 29.8% during the 1st quarter. BSW Wealth Partners now owns 22,430 shares of the company’s stock worth $312,000 after purchasing an additional 5,155 shares during the period. Finally, Legacy Wealth Asset Management LLC raised its stake in shares of Takeda Pharmaceutical by 1.3% during the 1st quarter. Legacy Wealth Asset Management LLC now owns 157,546 shares of the company’s stock worth $2,188,000 after purchasing an additional 2,018 shares during the period. 9.17% of the stock is currently owned by institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.